| Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis. | |
| | |
MedLine Citation:
|
PMID: 9438509 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
RATIONALE AND OBJECTIVES: The use of rapid dynamic magnetic resonance (MR) imaging after bolus intravenous contrast injection, to improve detection and delineation of parenchymal disease, was evaluated in an experimental model of splenic metastasis. METHODS: An experimental model for splenic metastasis was first developed in the New Zealand White rabbit. Magnetic resonance studies were then obtained at 1.5 tesla in six animals. A 25 ga needle was used to penetrate the spleen and inject 0.1 mL of minced, screened VX2 adenocarcinoma (obtained from a carrier rabbit). The injections were performed by two techniques, percutaneously using ultrasound guidance (n = 3) and at the time of abdominal laparotomy (n = 3). The animals were imaged at 1.5 tesla on day 10 after implantation. Breath-hold T2-weighted and T1-weighted scans were acquired prior to contrast injection. A dose of 0.3 mmol/kg gadoteridol (ProHance) was then administered intravenously using an MR-compatible power injector, with both dynamic and delayed postcontrast scans obtained. The lesion was confirmed in each animal by gross pathologic and microscopic exam. RESULTS: On region of interest analysis of T2-weighted scans, the lesions could not be differentiated by signal intensity (with any statistical significance) from normal surrounding splenic parenchyma. Lesion conspicuity, assessed by signal difference/noise ratio on dynamic turbo-FLASH scans, increased from 6+/-5 precontrast to a peak of 16+/-5 at 31 seconds postcontrast, with P < 0.003 (n = 6). Lesion conspicuity steadily diminished from this time to 5 minutes postinjection, although it was still improved at 5 minutes over precontrast scans. CONCLUSIONS: On early dynamic contrast enhanced breath-hold MR, marked improvement in the differentiation of splenic metastases from surrounding normal parenchyma is achieved. The capability of dynamic MR in this regard is analogous to that demonstrated for helical computed tomography. |
| | |
Authors:
|
V M Runge; N M Williams |
Related Documents
:
|
19512849 - Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate. 11469929 - Understanding why contrast enhancement in dynamic mri is not reproducible: illustration... 19036529 - An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imag... 17296999 - Dynamic 3d-ct angiography. 12110719 - Quantification of flow dynamics in congenital heart disease: applications of velocity-e... 19597719 - Symptoms of pelvic floor dysfunction are poorly correlated with findings on clinical ex... 10524809 - Visual quantitation and observer variation of signs of small airways disease at inspira... 11178689 - T2-weighted magnetic resonance imaging of the liver: comparison of fat-suppressed grase... 20466799 - Carotid atherosclerotic calcification does not result in high signal intensity in mr im... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Investigative radiology Volume: 33 ISSN: 0020-9996 ISO Abbreviation: Invest Radiol Publication Date: 1998 Jan |
Date Detail:
|
Created Date: 1998-03-05 Completed Date: 1998-03-05 Revised Date: 2009-11-11 |
Medline Journal Info:
|
Nlm Unique ID: 0045377 Medline TA: Invest Radiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 45-50 Citation Subset: IM |
Affiliation:
|
University of Kentucky, Lexington 40536-0098, USA. runge@pop.uky.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
pathology*,
secondary* Animals Contrast Media Disease Models, Animal Heterocyclic Compounds Magnetic Resonance Imaging* Neoplasm Transplantation Organometallic Compounds Rabbits Splenic Neoplasms / pathology*, secondary* Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; 0/Heterocyclic Compounds; 0/Organometallic Compounds; 112188-16-6/gadoteridol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intratumoral vascularity of experimentally induced VX2 carcinoma: comparison of color Doppler sonogr...
Next Document: Breast stereotactic core biopsy washings: abundant cell samples from clinically occult lesions for f...